Influence of Specific Immunotherapy With Pollinex Quattro (Tree-/Grass Pollen) on Allergen-specific Immunoglobulin E (IgE) Levels

Allergy Therapeutics

Status: Completed

Conditions: Allergic Conjunctivitis; Allergic Asthma; Respiratory Tract Infections; Allergy; Rhinitis, Allergic

Treatments: Drug: Pollinex Quattro with tree- and grass pollen extracts and their mixtures

Study type: Observational

Funder types: Industry

Identifiers

NCT04389034

PQ EAST V1.0

Details and patient eligibility

About

Primary goal of this non-interventional study is to evaluate the change in level of allergen-specific IgE (EAST class) after allergen-specific immunotherapy with Pollinex Quattro with tree and/or grass pollen extracts and their mixtures under medial routine at adults with tree- and/or grass-medicated pollinosis.

Full description

In this non-interventional study, the change in level of allergen-specific IgE before and after 3 or more years of allergen-specific immunotherapy with Pollinex Quattro in a patient population with tree and/or grass pollen induced pollinosis and/or asthma will be analyzed. In addition, the change in medication usage, asthma status for asthmatic patients after 3, 4 or 5 years of allergen specific immunotherapy will be evaluated. Furthermore, patients will be asked for their change in quality of life after therapy end.

Enrollment: 113 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients ≥ 18 years
• Diagnosis of IgE-mediated rhinitis, conjunctivitis and bronchial asthma on grass and/or tree pollen
• completed allergen-specific immunotherapy with Pollinex Quattro with tree and/or grass pollen extracts or their mixtures according to SMPC effective during immunotherapy

Exclusion criteria

• Contraindication according to Summary of Product Characteristics (SMPC) effective during immunotherapy
• no additional allergen-specific immunotherapy with another product than Pollinex Quattro

Trial design

113 participants in 1 patient group

Adults

Description:

Patients with IgE-induced Rhinitis, Conjunctivitis and/or asthma due to tree- and/or grass pollen induced allergy

Treatment:

Drug: Pollinex Quattro with tree- and grass pollen extracts and their mixtures